Compare Ascendis Pharma A/S (ASND) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs TKO Group Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while TKO Group Holdings Inc trades at $184.36 (market cap $13.82B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and TKO Group Holdings Inc pays a 1.69% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TKO | |
|---|---|---|
Market Cap | $17.74B | $13.82B |
Sector | Health | Technology |
52-Week High | $277.18 | $224.96 |
52-Week Low | $163.32 | $155.61 |
Enterprise Value | $18.11B | $18.00B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TKO trades at $184.4, down 2.01% today, with a bearish technical signal but strong analyst support. Recent earnings show a Q1 2026 beat but Q3 and Q4 2025 misses, while revenue grew to $4.74B in 2025. The company completed an $800 million share repurchase and announced a dividend, reflecting financial strength. Valuation ratios like P/E of 68.55 are elevated, but profitability margins improved.
Outlook is mixed: bullish analyst consensus with a $234 price target suggests upside, but high valuation and recent earnings volatility pose risks. Growth in live events and partnerships, like the UFC-Paramount deal, offers opportunities, yet execution and market sentiment remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
